The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(3-(6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-4-(1-methylpiperidin-4-ylamino)quinazolin-7-yl)propyl)acetamide ID: ALA4531347
PubChem CID: 155546390
Max Phase: Preclinical
Molecular Formula: C26H41N7O2
Molecular Weight: 483.66
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COc1cc2c(NC3CCN(C)CC3)nc(N3CCCN(C)CC3)nc2cc1CCCNC(C)=O
Standard InChI: InChI=1S/C26H41N7O2/c1-19(34)27-10-5-7-20-17-23-22(18-24(20)35-4)25(28-21-8-13-32(3)14-9-21)30-26(29-23)33-12-6-11-31(2)15-16-33/h17-18,21H,5-16H2,1-4H3,(H,27,34)(H,28,29,30)
Standard InChI Key: HAHIHYHVAXRHQR-UHFFFAOYSA-N
Molfile:
RDKit 2D
35 38 0 0 0 0 0 0 0 0999 V2000
28.7447 -26.3730 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
28.7436 -27.1925 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.4516 -27.6015 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.4498 -25.9641 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.1585 -26.3694 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.1592 -27.1884 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.8678 -27.5954 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5760 -27.1846 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.5713 -26.3625 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.8622 -25.9591 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.0356 -27.6005 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.4474 -25.1469 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
28.7385 -24.7404 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.0928 -28.4145 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.4931 -28.9724 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.3567 -27.1421 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.6857 -28.8550 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.5748 -27.3846 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2791 -28.1474 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.7386 -23.9197 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.0338 -23.5133 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.3249 -23.9206 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.3254 -24.7387 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.0347 -25.1496 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.6175 -23.5114 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2264 -29.5309 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2765 -25.9496 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
32.2715 -25.1324 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.2853 -27.5905 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.9914 -27.1791 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.7007 -27.5850 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.4068 -27.1736 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.1161 -27.5795 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8222 -27.1681 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1193 -28.3966 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 5 1 0
2 11 1 0
4 12 1 0
12 13 1 0
11 14 1 0
14 15 1 0
11 16 1 0
15 17 1 0
16 18 1 0
17 19 1 0
18 19 1 0
13 20 1 0
13 24 1 0
20 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
22 25 1 0
17 26 1 0
9 27 1 0
27 28 1 0
8 29 1 0
29 30 1 0
30 31 1 0
31 32 1 0
32 33 1 0
33 34 1 0
33 35 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 483.66Molecular Weight (Monoisotopic): 483.3322AlogP: 2.36#Rotatable Bonds: 8Polar Surface Area: 85.86Molecular Species: BASEHBA: 8HBD: 2#RO5 Violations: ┄HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 8.93CX LogP: 1.73CX LogD: -0.73Aromatic Rings: 2Heavy Atoms: 35QED Weighted: 0.55Np Likeness Score: -1.05
References 1. Leenders R, Zijlmans R, van Bree B, van de Sande M, Trivarelli F, Damen E, Wegert A, Müller D, Ehlert JE, Feger D, Heidemann-Dinger C, Kubbutat M, Schächtele C, Lenstra DC, Mecinović J, Müller G.. (2019) Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2., 29 (17): [PMID:31350126 ] [10.1016/j.bmcl.2019.06.012 ]